SEC Form 4 · accession 0001493152-26-027986
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seth Lederman
Officer — Chief Executive Officer · Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 9, 2026 · 5:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001430306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Jun 9, 2026 | P | 5,000 | $11.79 | A | 9,005 | D | |
| Common Stock, $0.001 par valueF2 | holding | — | — | — | 20,001 | I | By IRA Account | |
| Common Stock, $0.001 par valueF2 | holding | — | — | — | 1 | I | Lederman & Co. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.735 to $11.883 per share. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
- F2Reporting Person may be deemed a control person of this entity.